company background image
3006

Wuhan Hiteck Biological PharmaLtd SZSE:300683 Stock Report

Last Price

CN¥35.35

Market Cap

CN¥4.3b

7D

-4.5%

1Y

-15.0%

Updated

24 Sep, 2022

Data

Company Financials
300683 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance1/6
Financial Health3/6
Dividends0/6

300683 Stock Overview

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China.

Wuhan Hiteck Biological PharmaLtd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Wuhan Hiteck Biological PharmaLtd
Historical stock prices
Current Share PriceCN¥35.35
52 Week HighCN¥75.00
52 Week LowCN¥29.29
Beta-0.55
1 Month Change-12.61%
3 Month Change-8.23%
1 Year Change-15.04%
3 Year Change14.66%
5 Year Change-41.73%
Change since IPO-25.47%

Recent News & Updates

Shareholder Returns

300683CN BiotechsCN Market
7D-4.5%-4.7%-1.9%
1Y-15.0%-35.5%-18.6%

Return vs Industry: 300683 exceeded the CN Biotechs industry which returned -35.5% over the past year.

Return vs Market: 300683 exceeded the CN Market which returned -18.6% over the past year.

Price Volatility

Is 300683's price volatile compared to industry and market?
300683 volatility
300683 Average Weekly Movement6.3%
Biotechs Industry Average Movement4.8%
Market Average Movement5.8%
10% most volatile stocks in CN Market9.3%
10% least volatile stocks in CN Market3.7%

Stable Share Price: 300683 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 300683's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19921,143Ya Chenhttps://www.hiteck.com.cn

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye, an acyclovir dispensable tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository drug; Xunkeyuan, a tinidazole suppository drug; and Shufu, a nimodipine sustained release tablets. The company also provides measles virus and rubella virus nucleic acid detection kit; mycoplasma isolation and identification kit and culture tube; bacterial vaginosis rapid detection kit; measles virus IgG antibody detection kit; and coronavirus N-protein detection kit.

Wuhan Hiteck Biological PharmaLtd Fundamentals Summary

How do Wuhan Hiteck Biological PharmaLtd's earnings and revenue compare to its market cap?
300683 fundamental statistics
Market CapCN¥4.32b
Earnings (TTM)CN¥39.31m
Revenue (TTM)CN¥776.37m

109.8x

P/E Ratio

5.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
300683 income statement (TTM)
RevenueCN¥776.37m
Cost of RevenueCN¥399.86m
Gross ProfitCN¥376.51m
Other ExpensesCN¥337.20m
EarningsCN¥39.31m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.32
Gross Margin48.50%
Net Profit Margin5.06%
Debt/Equity Ratio3.4%

How did 300683 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 300683 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300683?

Other financial metrics that can be useful for relative valuation.

300683 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.4x
Enterprise Value/EBITDA78.7x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 300683's PE Ratio compare to its peers?

300683 PE Ratio vs Peers
The above table shows the PE ratio for 300683 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average36x
688136 Shandong Kexing Bioproducts Co.Ltd
103.4xn/aCN¥4.0b
688468 Chemclin Diagnostics
27xn/aCN¥3.8b
688767 Hangzhou Biotest BiotechLtd
4.8xn/aCN¥4.9b
300149 Chempartner Pharmatech
8.8xn/aCN¥4.8b
300683 Wuhan Hiteck Biological PharmaLtd
109.8xn/aCN¥4.3b

Price-To-Earnings vs Peers: 300683 is expensive based on its Price-To-Earnings Ratio (109.8x) compared to the peer average (36x).


Price to Earnings Ratio vs Industry

How does 300683's PE Ratio compare vs other companies in the CN Biotechs Industry?

Price-To-Earnings vs Industry: 300683 is expensive based on its Price-To-Earnings Ratio (109.8x) compared to the CN Biotechs industry average (29.6x)


Price to Earnings Ratio vs Fair Ratio

What is 300683's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300683 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio109.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 300683's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 300683 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 300683's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 300683's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Wuhan Hiteck Biological PharmaLtd forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


26.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wuhan Hiteck Biological PharmaLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of 300683’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has Wuhan Hiteck Biological PharmaLtd performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-50.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 300683 has a high level of non-cash earnings.

Growing Profit Margin: 300683 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 300683's earnings have declined by 50.7% per year over the past 5 years.

Accelerating Growth: 300683 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 300683 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (6.5%).


Return on Equity

High ROE: 300683's Return on Equity (2.1%) is considered low.


Discover strong past performing companies

Financial Health

How is Wuhan Hiteck Biological PharmaLtd's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 300683's short term assets (CN¥1.5B) exceed its short term liabilities (CN¥243.5M).

Long Term Liabilities: 300683's short term assets (CN¥1.5B) exceed its long term liabilities (CN¥82.9M).


Debt to Equity History and Analysis

Debt Level: 300683 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 300683's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 300683's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if 300683's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies

Dividend

What is Wuhan Hiteck Biological PharmaLtd current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 300683's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 300683's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 300683's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 300683's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: 300683 is not paying a notable dividend for the CN market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 300683 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average board tenure


CEO

Ya Chen (50 yo)

no data

Tenure

CN¥634,300

Compensation

Mr. Chen Ya serves as General Manager at Wuhan Hiteck Biological Pharma Co., Ltd. Mr. Chen serves as the General Manager of Yiyuan Tang Health Science and Technology Co., Ltd. He served as Deputy General M...


Board Members

Experienced Board: 300683's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.1%.


Top Shareholders

Top 7 shareholders own 43.75% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
32.76%
Wuhan Sanjiangyuan Investment Development Co., Ltd.
40,000,000CN¥1.4b0%no data
9.05%
Ya Chen
11,050,000CN¥390.6m0%no data
1.03%
Jie Yan
1,263,000CN¥44.6m0%no data
0.77%
Jingmen High-Tech Industrial Development Co., Ltd.
937,500CN¥33.1m0%no data
0.096%
E Fund Management Co., Ltd.
117,400CN¥4.2m146.12%no data
0.045%
GF Fund Management Co., Ltd.
55,345CN¥2.0m0%no data
0.00016%
Sheng Qiang Li
200CN¥7.1k0%no data

Company Information

Wuhan Hiteck Biological Pharma Co.,Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Wuhan Hiteck Biological Pharma Co.,Ltd
  • Ticker: 300683
  • Exchange: SZSE
  • Founded: 1992
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CN¥4.316b
  • Shares outstanding: 122.10m
  • Website: https://www.hiteck.com.cn

Number of Employees


Location

  • Wuhan Hiteck Biological Pharma Co.,Ltd
  • Hite Science and Technology Park
  • Economic Development Zone
  • Wuhan
  • Hubei Province
  • 430056
  • China


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
300683SZSE (Shenzhen Stock Exchange)YesDomestic SharesCNCNYAug 2017

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/24 00:00
End of Day Share Price2022/09/23 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.